# Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

> **NCT00396084** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 70 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Gatifloxacin
- **DRUG:** Isoniazid
- **DRUG:** Levofloxacin
- **DRUG:** Linezolid
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT00396084
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02-10
- **Primary completion:** 2007-11-23
- **Final completion:** 2007-12-28
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396084, "Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00396084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*